Medicare Details Reimbursement for Alzheimer’s Drug

The U.S. Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai Co Ltd and Biogen Inc’s new Alzheimer’s drug Leqembi, should it win traditional U.S. approval as expected by July 6. Under the plan,…

Read Full Article (External Site)